Hypha Labs' Revolutionary Psilocybin Bioreactor Nominated for Best New Product of 2024 by Santa Monica Daily Press
Hypha Labs (OTC PINK:FUNI) has received a nomination for its proprietary bioreactor as "Best New Product of 2024" by the Santa Monica Daily Press (SMDP). The bioreactor, which produces specialized mushroom ingredients including psilocybin in approximately eight days, has been praised for its groundbreaking technological advancement in mushroom production.
The SMDP article highlights the potential wide-reaching impact of Hypha Labs' innovation on the scientific community, mental health system, and consumers. Stone Douglass, CEO of Hypha Labs, expressed honor at the recognition and emphasized the company's commitment to bringing a revolutionary device to market as they prepare for a full commercial launch in the coming months.
Hypha Labs (OTC PINK:FUNI) ha ricevuto una nomination per il suo bioreattore proprietario come "Miglior Nuovo Prodotto del 2024" da parte del Santa Monica Daily Press (SMDP). Il bioreattore, che produce ingredienti specializzati a base di fungo inclusi psilocibina in circa otto giorni, è stato elogiato per il suo avanzamento tecnologico innovativo nella produzione di funghi.
L'articolo della SMDP mette in evidenza il potenziale impatto di vasta portata dell'innovazione di Hypha Labs sulla comunità scientifica, sul sistema di salute mentale e sui consumatori. Stone Douglass, CEO di Hypha Labs, ha espresso onore per il riconoscimento e ha sottolineato l'impegno dell'azienda nel portare sul mercato un dispositivo rivoluzionario mentre si preparano per un lancio commerciale completo nei prossimi mesi.
Hypha Labs (OTC PINK:FUNI) ha recibido una nominación para su bioreactor patentado como "Mejor Nuevo Producto de 2024" por el Santa Monica Daily Press (SMDP). El bioreactor, que produce ingredientes especializados de setas incluyendo psilocibina en aproximadamente ocho días, ha sido elogiado por su avance tecnológico innovador en la producción de setas.
El artículo de SMDP destaca el potencial profundo impacto de la innovación de Hypha Labs en la comunidad científica, el sistema de salud mental y los consumidores. Stone Douglass, CEO de Hypha Labs, expresó su honor por el reconocimiento y enfatizó el compromiso de la empresa de llevar al mercado un dispositivo revolucionario mientras se preparan para un lanzamiento comercial completo en los próximos meses.
하이파랩스 (OTC PINK:FUNI)가 산타 모니카 데일리 프레스 (SMDP)에 의해 "2024년 최고의 신제품"으로 독자적인 바이오 리액터에 대해 지명을 받았습니다. 이 바이오 리액터는 약 8일 만에 버섯 재료를 포함한 환각버섯을 생산하여 버섯 생산에서 만큼은 획기적인 기술 진보로 높이 평가받았습니다.
SMDP 기사는 하이파랩스의 혁신이 과학 공동체, 정신 건강 시스템 및 소비자에게 미칠 잠재적인 광범위한 영향을 강조합니다. 스톤 더글라스 하이파랩스 CEO는 이 인정을 받게 되어 영광이라며, 다가오는 몇 달 안에 완전 상업적 출시를 준비하면서 혁신적인 장치를 시장에 선보이려는 회사의 헌신을 강조했습니다.
Hypha Labs (OTC PINK:FUNI) a reçu une nomination pour son bioréacteur propriétaire en tant que "Meilleur Nouveau Produit de 2024" par le Santa Monica Daily Press (SMDP). Le bioréacteur, qui produit des ingrédients de champignon spécialisés, y compris la psilocybine en environ huit jours, a été salué pour son avancée technologique révolutionnaire dans la production de champignons.
L'article de SMDP souligne l'impact potentiel à grande échelle de l'innovation de Hypha Labs sur la communauté scientifique, le système de santé mentale et les consommateurs. Stone Douglass, PDG de Hypha Labs, a exprimé son honneur à recevoir cette reconnaissance et a souligné l'engagement de l'entreprise à commercialiser un dispositif révolutionnaire alors qu'ils se préparent à un lancement commercial complet dans les mois à venir.
Hypha Labs (OTC PINK:FUNI) hat eine Nominierung für seinen eigenen Bioreaktor als "Bestes Neues Produkt 2024" von der Santa Monica Daily Press (SMDP) erhalten. Der Bioreaktor, der innerhalb von etwa acht Tagen spezialisierte Pilzzutaten einschließlich Psilocybin produziert, wurde für seinen bahnbrechenden technologischen Fortschritt in der Pilzproduktion gelobt.
Der Artikel der SMDP hebt das potenzielle weitreichende Auswirkungen der Innovation von Hypha Labs auf die wissenschaftliche Gemeinschaft, das psychische Gesundheitssystem und die Verbraucher hervor. Stone Douglass, CEO von Hypha Labs, drückte seine Ehrfurcht über die Auszeichnung aus und betonte das Engagement des Unternehmens, ein revolutionäres Gerät auf den Markt zu bringen, während sie sich auf eine vollständige kommerzielle Einführung in den kommenden Monaten vorbereiten.
- Nomination for 'Best New Product of 2024' by Santa Monica Daily Press
- Proprietary bioreactor produces specialized mushroom ingredients in 8 days
- Potential impact on scientific community, mental health system, and consumers
- Preparing for full commercial launch in coming months
- None.
LAS VEGAS, NV / ACCESSWIRE / August 20, 2024 / Hypha Labs, Inc. (OTC PINK:FUNI), a pioneer in functional mushroom sciences, is pleased to announce that the Company's proprietary bioreactor which allows individuals and companies to produce specialized mushroom ingredients such as psilcybin, has been nominated as "Best New Product of 2024" by the Santa Monica Daily Press (SMDP).
The Hypha Bioreactor which produces mushroom ingredients in eight days on average.
In the article, the Santa Monica Daily Press refers to Hypha Lab's flagship product, lauding its "groundbreaking technological advancement in the landscape and production of psilocybin mushrooms."
The article goes on to note Hypha Lab's potential impact on society, stating "As Hypha Labs continues to innovate, the potential benefits of the bioreactor will likely be felt far and wide, impacting the scientific community, mental health system, and consumers in need."
"We are honored to be acknowleged by an important voice in the Santa Monica Daily Press," stated Stone Douglass, CEO, Hypha Labs. "We are still at the very beginning of our journey as we prepare a full commercial launch in the coming months and accolades such as this from independent voices are important to our team and to potential partners."
"And it is important as we roll-out what I firmly believe is a revolutionary device that's looking to change so much in a revolutionary industry to be worthy of this high praise," added Douglass. "I can tell you that we are doing our level best to bring to market the most convenient, reliable and effective at-home producer of mushroom ingredients that this industry, that this wellness movement, has ever seen."
The article is available in full at the following link:
About Hypha Labs, Inc.
The company has developed revolutionary cutting-edge technology focused on new methods of producing the active ingredients found in functional mushrooms such as psilocybin using its patent-pending bioreactor design. The Company has positioned itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in the psilocybin space which is quickly manifesting into a similar pattern that was seen in the Cannabis Industry both from a medical and recreational usage with several states and cities have now decriminalized it use. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
Investor and Media Relations:
Integrity Media Inc.
(888) 216-3595
team@integritymedia.com
Contact Information
Kurt Divich
President, Integrity Media Inc.
team@integritymedia.com
(888) 216-3595
SOURCE: Company
View the original press release on accesswire.com
FAQ
What product has Hypha Labs (FUNI) been nominated for in 2024?
How long does it take for Hypha Labs' (FUNI) bioreactor to produce mushroom ingredients?
When is Hypha Labs (FUNI) planning to launch its bioreactor commercially?
What potential impacts does the Santa Monica Daily Press highlight for Hypha Labs' (FUNI) bioreactor?
